HLS 24RS-3545 ORIGINAL

2024 Regular Session

1

HOUSE CONCURRENT RESOLUTION NO. 96

BY REPRESENTATIVE BROWN

INSURANCE/HEALTH: Requests the Department of Insurance to study the impact of alternative funding programs on patient access to affordable prescription drugs

A CONCURRENT RESOLUTION

2	To authorize and request the Department of Insurance to create the Louisiana Alternative
3	Funding Program Task Force to study the impact of alternative funding programs on
4	patient access to affordable prescription drugs.
5	WHEREAS, ensuring access to medically necessary medication is critical to the
6	health outcomes of patients in Louisiana; and
7	WHEREAS, according to survey data, as many as eight percent of health coverage
8	plans are using alternative funding programs, and thirty-one percent are exploring their use;
9	and
10	WHEREAS, alternative funding program vendors have been reported to remove
11	health plan coverage for specialty drugs prescribed to a patient or specialty drugs altogether,
12	despite the fact that the patient continues to make payments for prescription drug coverage
13	under a health coverage plan; and
14	WHEREAS, an alternative funding program's removal of coverage may be done to
15	disguise the patient as uninsured or underinsured for the purpose of the patient applying and
16	qualifying for assistance from needs-based patient assistance programs; and
17	WHEREAS, shifting of patients who otherwise have purchased prescription drug
18	coverage to patient assistance programs could threaten the availability of needs-based
19	assistance for those who truly qualify for the use of patient assistance programs; and
20	WHEREAS, a patient assistance program may reject patients when detecting that the
21	patient is being disguised as uninsured, leading to significant delays in care, loss of access

29

1 to medication, or causing a forced switch to a medication not prescribed by the patient's 2 doctor; and 3 WHEREAS, it is important for Louisiana to ensure that patient assistance programs 4 remain sustainable and available to support the population for which they are intended. 5 THEREFORE, BE IT RESOLVED that the Legislature of Louisiana does hereby 6 authorize and request the Department of Insurance to create the Louisiana Alternative 7 Funding Program Task Force to study the impact of alternative funding programs on patient 8 access to affordable prescription drugs. 9 BE IT FURTHER RESOLVED that the Louisiana Alternative Funding Program Task 10 Force shall be comprised of the following members: 11 (1) The commissioner of insurance. 12 (2) The chief executive officer of the Louisiana State Medical Society. (3) The executive director of the Louisiana Oncology Society. 13 14 (4) The president of the Rheumatology Alliance of Louisiana. 15 (5) The executive director of the Coalition of State Rheumatology Organizations. 16 (6) The chief executive officer of the Louisiana Association of Health Plans. 17 (7) The president of Health Agents for America. 18 (8) The president of the Pharmaceutical Care Management Association. 19 (9) The chief executive officer of Pharmaceutical Research and Manufacturers of 20 America. 21 (10) The chief executive officer of the Louisiana Independent Pharmacies 22 Association. 23 BE IT FURTHER RESOLVED that the Louisiana Alternative Funding Program Task 24 Force shall study all of the following: 25 (1) The history and prevalence of alternative funding programs in the United States 26 and Louisiana, including but not limited to the types of health insurance products that utilize, 27 all or in part, alternative funding programs to provide access, coverage, or discounts for 28 prescription drugs.

(2) The business model of alternative funding programs.

(3) The impact of alternative funding programs on patient assistance programs for
prescription medications, including but not limited to long-term stability of those patient
assistance programs if an upswing in alternative funding programs is realized across an
increased number of health insurance products.
(4) The impact of alternative funding programs on coverage of prescription
medications if the utilization of alternative funding programs is expanded across additional
insurance products, including but not limited to commercial health coverage plans, health
coverage plans offered to public employees, and health coverage plans offered to individuals
in the state's health insurance exchange.
BE IT FURTHER RESOLVED that the commissioner of insurance shall serve as the
chairman of the task force and the staff of the Department of Insurance shall provide support
to the task force.
BE IT FURTHER RESOLVED that each appointed member of the task force may
appoint a designee who shall serve on the task force on his behalf.
BE IT FURTHER RESOLVED that the members of the task force shall serve
without compensation, except per diem or expense reimbursement to which they may be
individually entitled as members of their constituent organizations.
BE IT FURTHER RESOLVED that a majority of the total membership shall
constitute a quorum of the task force, and any official action by the task force shall require
an affirmative vote of a majority of the quorum present and voting.
BE IT FURTHER RESOLVED that the names of the members designated in this
Resolution shall be submitted to the chairman of the task force by July 15, 2024, and the
chairman shall thereafter call the first meeting of the task force by August 15, 2024.
BE IT FURTHER RESOLVED that the task force shall meet as necessary and
provide a written report of its findings from the study, together with any recommendations
for legislation, to the House Committee on Insurance, the Senate Committee on Insurance,
and the David R. Poynter Legislative Research Library no later than December 31, 2024.
BE IT FURTHER RESOLVED that the task force shall terminate upon the date of
submission of its report.

BE IT FURTHER RESOLVED that a copy of this Resolution be transmitted to the

- 2 commissioner of insurance, the chief executive officer of the Louisiana State Medical
- 3 Society, the executive director of the Louisiana Oncology Society, the president of the
- 4 Rheumatology Alliance of Louisiana, the executive director of the Coalition of State
- 5 Rheumatology Organizations, the chief executive officer of the Louisiana Association of
- 6 Health Plans, the president of Health Agents for America, the president of the
- 7 Pharmaceutical Care Management Association, the chief executive officer of Pharmaceutical
- 8 Research and Manufacturers of America, and the chief executive officer of the Louisiana
- 9 Independent Pharmacies Association.

DIGEST

The digest printed below was prepared by House Legislative Services. It constitutes no part of the legislative instrument. The keyword, one-liner, abstract, and digest do not constitute part of the law or proof or indicia of legislative intent. [R.S. 1:13(B) and 24:177(E)]

HCR 96 Original

2024 Regular Session

Brown

Creates the La. Alternative Funding Program Task Force to study and make recommendations regarding the impact of alternative funding programs on patient access to affordable prescription drugs.

Specifies the members of the task force and provides that members serve without compensation, except for such reimbursement or per diem they are individually entitled to as members of the constituent groups they represent.

Requests the task force to report its findings, with any recommendations for legislation, no later than Dec. 1, 2024.